Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 46

1.

Ruxolitinib as monotherapy in a patient with anaplastic lymphoma kinase positive lung adenocarcinoma.

Koršić M, Muršić D, Badovinac S, Roglić M, Jakopović M, Zupančić Šalek S, Samaržija M.

Anticancer Drugs. 2019 Nov;30(10):1061-1063. doi: 10.1097/CAD.0000000000000822.

PMID:
31609765
2.

Subcutaneous concizumab prophylaxis in hemophilia A and hemophilia A/B with inhibitors: phase 2 trial results.

Shapiro AD, Angchaisuksiri P, Astermark J, Benson G, Castaman G, Chowdary P, Eichler H, Jiménez-Yuste V, Kavakli K, Matsushita T, Poulsen LH, Wheeler AP, Young G, Zupancic-Salek S, Oldenburg J.

Blood. 2019 Nov 28;134(22):1973-1982. doi: 10.1182/blood.2019001542.

PMID:
31444162
3.

Inhibitors in haemophilia A and B: Management of bleeds, inhibitor eradication and strategies for difficult-to-treat patients.

Ljung R, Auerswald G, Benson G, Dolan G, Duffy A, Hermans C, Jiménez-Yuste V, Lambert T, Morfini M, Zupančić-Šalek S, Santagostino E.

Eur J Haematol. 2019 Feb;102(2):111-122. doi: 10.1111/ejh.13193. Epub 2018 Dec 6. Review.

PMID:
30411401
4.

Long-term safety and efficacy of turoctocog alfa in prophylaxis and treatment of bleeding episodes in severe haemophilia A: Final results from the guardian 2 extension trial.

Lentz SR, Janic D, Kavakli K, Miljic P, Oldenburg J, C Ozelo M, Santagostino E, Suzuki T, Zupancic Šalek S, Korsholm L, Matytsina I, Tiede A.

Haemophilia. 2018 Nov;24(6):e391-e394. doi: 10.1111/hae.13617. Epub 2018 Nov 6.

PMID:
30402994
5.

Influence of Blood Count, Cardiovascular Risks, Inherited Thrombophilia, and JAK2 V617F Burden Allele on Type of Thrombosis in Patients With Philadelphia Chromosome Negative Myeloproliferative Neoplasms.

Horvat I, Boban A, Zadro R, Antolic MR, Serventi-Seiwerth R, Roncevic P, Radman I, Sertic D, Vodanovic M, Pulanic D, Basic-Kinda S, Durakovic N, Zupancic-Salek S, Vrhovac R, Aurer I, Nemet D, Labar B.

Clin Lymphoma Myeloma Leuk. 2019 Jan;19(1):53-63. doi: 10.1016/j.clml.2018.08.020. Epub 2018 Sep 10.

PMID:
30301673
6.

Practical aspects of extended half-life products for the treatment of haemophilia.

Lambert T, Benson G, Dolan G, Hermans C, Jiménez-Yuste V, Ljung R, Morfini M, Zupančić-Šalek S, Santagostino E.

Ther Adv Hematol. 2018 Sep 6;9(9):295-308. doi: 10.1177/2040620718796429. eCollection 2018 Sep. Review.

7.

Extensive Deep Venous Thrombosis in a Young Male Patient as the First Manifestation of a Rare Venous Anomaly - Inferior Vena Cava Duplication: Case Report.

Pulanić D, Ranković E, Vodanović M, Lušić M, Boban A, Zupančić Šalek S, Nemet D.

Acta Clin Croat. 2017 Jun;56(2):338-343. doi: 10.20471/acc.2017.56.02.19.

PMID:
29485803
8.

A case report of acute inferior myocardial infarction in a patient with severe hemophilia A after recombinant factor VIII infusion.

Zupančić-Šalek S, Vodanović M, Pulanić D, Skorić B, Matytsina I, Klovaite J.

Medicine (Baltimore). 2017 Dec;96(52):e9075. doi: 10.1097/MD.0000000000009075.

9.

Association of Plasminogen Activator Inhibitor-1 Gene Polymorphisms and Methylene Tetrahydrofolate Reductase Polymorphisms with Spontaneous Miscarriages.

Bubalo P, Buterin I, Šalek Z, Ðogić V, Zupančić-Šalek S.

Acta Haematol. 2017;138(2):111-115. doi: 10.1159/000478084. Epub 2017 Sep 1.

PMID:
28858863
10.

Haemophilia B: Where are we now and what does the future hold?

Dolan G, Benson G, Duffy A, Hermans C, Jiménez-Yuste V, Lambert T, Ljung R, Morfini M, Zupančić Šalek S.

Blood Rev. 2018 Jan;32(1):52-60. doi: 10.1016/j.blre.2017.08.007. Epub 2017 Aug 16. Review.

PMID:
28826659
11.

Outcome measures for adult and pediatric hemophilia patients with inhibitors.

Hermans C, Auerswald G, Benson G, Dolan G, Duffy A, Jiménez-Yuste V, Ljung R, Morfini M, Lambert T, Osooli M, Zupančić Šalek S.

Eur J Haematol. 2017 Aug;99(2):103-111. doi: 10.1111/ejh.12881. Epub 2017 Apr 25. Review.

PMID:
28332238
12.

Once-weekly prophylactic treatment vs. on-demand treatment with nonacog alfa in patients with moderately severe to severe haemophilia B.

Kavakli K, Smith L, Kuliczkowski K, Korth-Bradley J, You CW, Fuiman J, Zupančić-Šalek S, Abdul Karim F, Rendo P.

Haemophilia. 2016 May;22(3):381-8. doi: 10.1111/hae.12878. Epub 2016 Jan 29.

PMID:
26823276
13.

Venous thromboembolism in Croatia - Croatian Cooperative Group for Hematologic Diseases (CROHEM) study.

Pulanić D, Gverić-Krečak V, Nemet-Lojan Z, Holik H, Coha B, Babok-Flegarić R, Komljenović M, Knežević D, Petrovečki M, Zupančić Šalek S, Labar B, Nemet D.

Croat Med J. 2015 Dec;56(6):550-7.

14.

Changes in the amino acid sequence of the recombinant human factor VIIa analog, vatreptacog alfa, are associated with clinical immunogenicity.

Mahlangu JN, Weldingh KN, Lentz SR, Kaicker S, Karim FA, Matsushita T, Recht M, Tomczak W, Windyga J, Ehrenforth S, Knobe K; adept™2 Investigators.

J Thromb Haemost. 2015 Nov;13(11):1989-98. doi: 10.1111/jth.13141. Epub 2015 Oct 13.

15.

First prospective report on immune tolerance in poor risk haemophilia A inhibitor patients with a single factor VIII/von Willebrand factor concentrate in an observational immune tolerance induction study.

Kreuz W, Escuriola Ettingshausen C, Vdovin V, Zozulya N, Plyushch O, Svirin P, Andreeva T, Bubanská E, Campos M, Benedik-Dolničar M, Jiménez-Yuste V, Kitanovski L, Klukowska A, Momot A, Osmulskaya N, Prieto M, Šalek SZ, Velasco F, Pavlova A, Oldenburg J, Knaub S, Jansen M, Belyanskaya L, Walter O; ObsITI study group; ObsITI committee.

Haemophilia. 2016 Jan;22(1):87-95. doi: 10.1111/hae.12774. Epub 2015 Jul 23.

PMID:
26202305
16.

Tailoring care to haemophilia patients' needs: which specialty and when?

Morfini M, Benson G, Jiménez-Yuste V, Ljung R, Mannucci PM, Pasta G, Remor E, Zupančić Šalek S.

Blood Transfus. 2015 Oct;13(4):644-50. doi: 10.2450/2015.0302-14. Epub 2015 May 20. No abstract available.

17.

Quantitative ultrasound and dual energy X-ray absorptiometry in the assessment of osteoporosis in patients with haemophilia.

Boban A, Zupancic Salek S, Kastelan D, Nemet D.

Haemophilia. 2014 Nov;20(6):e420-2. doi: 10.1111/hae.12529. No abstract available.

PMID:
25354773
18.

New quantitative aPTT waveform analysis and its application in laboratory management of haemophilia A patients.

Milos M, Coen Herak D, Zupancic-Salek S, Zadro R.

Haemophilia. 2014 Nov;20(6):898-904. doi: 10.1111/hae.12492. Epub 2014 Oct 2.

PMID:
25273337
19.

Switching treatments in haemophilia: is there a risk of inhibitor development?

Santagostino E, Auerswald G, Benson G, Dolan G, Jiménez-Yuste V, Lambert T, Ljung R, Morfini M, Remor E, Zupančić Šalek S.

Eur J Haematol. 2015 Apr;94(4):284-9. doi: 10.1111/ejh.12433. Epub 2014 Sep 17. Review.

20.

Recombinant factor VIIa analog in the management of hemophilia with inhibitors: results from a multicenter, randomized, controlled trial of vatreptacog alfa.

Lentz SR, Ehrenforth S, Karim FA, Matsushita T, Weldingh KN, Windyga J, Mahlangu JN; adept™2 investigators.

J Thromb Haemost. 2014 Aug;12(8):1244-53. doi: 10.1111/jth.12634. Epub 2014 Jul 16.

Supplemental Content

Loading ...
Support Center